Further, presentations included an update on the applications of ‘C12-200’ lipidoid-based cationic LNP formulations that achieve extremely powerful in vivo gene silencing efficacy in a non-ApoE-dependent manner. Additional results linked to the rational design of novel cationic and ionizable lipids that demonstrate improved properties for systemic delivery of RNAi therapeutics were also reported. Finally, results were presented linked to the translation of LNPs into medical advancement, including Alnylam’s ALN-VSP and ALN-TTR applications developed in collaboration with Tekmira, which make use of an LNP formulation referred to as steady nucleic acid lipid particle .Our results may actually demonstrate that vigabatrin induced satiety in these animals, said Amy DeMarco, who led the study, working in the laboratory of Brookhaven Lab senior scientist Stephen Dewey. Dewey first determined vigabatrin as a potential addiction treatment and provides conducted more than 20 years of preclinical research with this promising medication. Earlier research at Brookhaven Lab found a solid connection between weight problems and addiction, including similar adjustments in the brains of the obese and the ones addicted to drugs like cocaine. Predicated on these connections, Dewey hypothesized that vigabatrin would quench food cravings in the laboratory rats.